Results 31 to 40 of about 17,219,459 (310)
LAG-3 in Cancer Immunotherapy [PDF]
, 2010 LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al.
Monica V, Goldberg, Charles G, Drake
openaire +2 more sources
LAG-3 expression in the inflammatory microenvironment of glioma [PDF]
Journal of Neuro-Oncology, 2021 Abstract Purpose Immune modulatory therapies including immune checkpoint inhibitors have so far failed to result in clinically meaningful efficacy in glioma. We aimed to investigate lymphocyte activation gene 3 (LAG-3), an inhibitory receptor on immune cells and target of second-generation immune checkpoint inhibitors ...
Maximilian J. Mair +8 more
openaire +2 more sources
Immune checkpoints in circulating and tumor-Infiltrating CD4 + T Cell Subsets in Colorectal cancer patients [PDF]
, 2019 Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach; however, it has shown limited success in some cancers including colorectal cancer (CRC). The tumor microenvironment (TME) is largely responsible for response to therapy,
Abu Nada, M +5 more
core +2 more sources
European Journal of Nuclear Medicine and Molecular Imaging, 2023 Purpose Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking.
Iris H. C. Miedema +13 more
semanticscholar +1 more source
, 2017 Co-inhibitory receptors play a key role in regulating T cell responses and maintaining immune homeostasis. Their inhibitory function prevents autoimmune responses but also restricts the ability of T cells to mount effective immune responses against tumors or persistent pathogens.
Joller, Nicole, Kuchroo, Vijay K.
openaire +3 more sources
Immunity, 2022 Lymphocyte activation gene-3 (LAG-3) is a potent inhibitory co-receptor; yet, its functional ligand remains elusive, with distinct potential ligands identified.
Takumi Maruhashi +11 more
semanticscholar +1 more source
Genomic and immunologic correlates of LAG-3 expression in cancer
OncoImmunology, 2020 Immune checkpoint blockade leads to unprecedented responses in many cancers. Although currently available agents mostly target the PD-1 and CTLA-4 pathways, agents targeting the immune checkpoint protein LAG-3 are under active clinical development, and ...
Anshuman Panda +4 more
doaj +1 more source
Biological therapy in the treatment of melanoma [PDF]
, 2018 Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile +8 more
core +3 more sources
Journal of Clinical Investigation, 2023 Background Relatlimab plus nivolumab (anti–lymphocyte-activation gene 3 plus anti–programmed death 1 [anti–LAG-3+anti–PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is ...
Jani Huuhtanen +19 more
semanticscholar +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment
P. Schöffski +31 more
semanticscholar +1 more source